Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (symbol: PSTV) is a cutting-edge clinical-stage pharmaceutical company based in Austin, Texas. Founded in 1996 and initially known as Cytori Therapeutics, Inc., the company rebranded to Plus Therapeutics in July 2019 to better reflect its mission and evolving focus. Specializing in the discovery, development, and manufacture of innovative treatments for cancer and other debilitating diseases, Plus Therapeutics aims to bring new hope to patients through cutting-edge medical solutions.
The company's lead product candidate is DocePLUS, a protein-stabilized, pegylated liposomal formulation of docetaxel specifically designed for the treatment of small cell lung cancer. Additionally, Plus Therapeutics is developing DoxoPLUS, a generic pegylated liposomal encapsulated doxorubicin aimed at treating breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma.
In a significant partnership, Plus Therapeutics has entered into a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. This collaboration aims to propel the company further into the forefront of cancer treatment research.
One of the company's groundbreaking developments is the novel injectable radiotherapy called Rhenium (186Re) obisbemeda. This treatment is specifically formulated to deliver targeted high-dose radiation in Central Nervous System (CNS) tumors, optimizing patient outcomes while minimizing off-target risks. The product's efficacy and safety are being evaluated for recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. These trials are supported by grants from the National Cancer Institute (NCI) and the Cancer Prevention & Research Institute of Texas (CPRIT), totaling millions in funding.
Financially, Plus Therapeutics recently secured $6.5 million in upfront gross proceeds, with the potential to receive up to an additional $11.5 million through potential warrant exercise, amounting to approximately $18 million in total gross proceeds. These funds will be essential in advancing the company’s robust pipeline and bringing innovative treatments to market.
Investors and stakeholders can stay informed of the latest developments and financial updates by reaching out to key contacts such as Corey Davis, Ph.D. of LifeSci Advisors, and Charles Y. Huang, MBA, Director of Capital Markets and Investor Relations.
Plus Therapeutics (Nasdaq: PSTV) will present new data on its Leptomeningeal Metastases (LM) programs at the 2024 SNO/ASCO CNS Metastases Conference. The company will host a symposium on 'Emerging Novel Diagnostic and Therapeutic Approaches for Leptomeningeal Metastases' on August 8. Key presentations include:
1. Phase 1 dose escalation study of Rhenium (186Re) Obisbemeda for LM treatment
2. Radiation absorbed dose to spinal cord in LM therapy using beta-emission radiopharmaceuticals
3. CSF Tumor Cell detection for clinical management of breast and lung cancer patients with LM
4. CNSide CSF Tumor Cell detection platform for LM disease management
These presentations highlight Plus Therapeutics' progress in both therapeutic and diagnostic approaches for LM, a challenging area in central nervous system cancers.
Plus Therapeutics (Nasdaq: PSTV), a clinical-stage pharmaceutical firm, announced that Dr. Melissa Moore, VP of Clinical Research and Development, will present at the Gordon Research Conference on July 8, 2024, in Newry, Maine. The presentation, scheduled for 11:30 a.m. EDT, will cover data from the ReSPECT-GBM and ReSPECT-LM studies. These trials evaluate the company's lead radiotherapeutic, rhenium (186Re) obisbemeda, for treating recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Plus Therapeutics focuses on developing targeted radiotherapeutics for CNS cancers, utilizing advanced platform technologies and strategic partnerships for potential product commercialization.
Plus Therapeutics has appointed Dr. Greg Fuller as Vice President of Medical Affairs and Medical Director. Fuller, formerly with The University of Texas MD Anderson Cancer Center, will help implement the CNSide® cerebrospinal fluid cancer diagnostic portfolio. Plus also received a $3.3 million advance payment from CPRIT for its leptomeningeal cancer radiotherapeutic program, part of a $17.6 million award from 2022. CNSide, used in the ReSPECT-LM clinical trial, is expected to launch commercially by Q4 2024. CNSide is over 90% sensitive for detecting leptomeningeal metastases, potentially expanding the market for Plus' lead candidate, rhenium (Re186) obisbemeda. The $3.3M funding will support ongoing clinical developments and validation of CNSide. Fuller received option awards for 13,116 shares of Plus stock, vesting over four years.
Plus Therapeutics announced on May 17, 2024, that it has granted option awards to Charles Huang, their new Director of Capital Markets and Investor Relations. The awards, given on May 8, 2024, include options to purchase up to 5,000 shares of Plus Therapeutics' common stock. These options will vest over four years, with one-fourth vesting after the first year and the remainder vesting monthly. The exercise price is set at the closing price on the grant date, May 8, 2024. This initiative aims to align the interests of Mr. Huang with the company’s shareholders. These awards were granted outside the 2020 Incentive Plan but follow similar terms.
Plus Therapeutics (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on central nervous system cancers, announced its Q1 2024 financial results and business highlights.
The company closed a private placement financing for initial gross proceeds of $7.25 million, with a potential total of $19.25 million. Plus also received a $3 million award recommendation from the Department of Defense for its brain cancer program. Additionally, it acquired a diagnostic portfolio for leptomeningeal metastases and reported positive clinical trial data.
Financially, the company reported a decrease in operating loss to $3.3 million from $4.8 million in Q1 2023, and a net loss of $3.3 million, or $(0.75) per share, compared to a net loss of $4.8 million, or $(2.07) per share, in the same period last year.
Upcoming milestones include several scientific presentations and potential FDA feedback on various clinical trials and applications.
Plus Therapeutics, Inc. will announce its first quarter 2024 financial results on May 15, 2024, after market close. The company is a clinical-stage pharmaceutical company focusing on developing targeted radiotherapeutics for central nervous system cancers. Plus Therapeutics' management team will host a conference call and webcast at 5:00 p.m. ET on the same day to discuss the financial results and provide a corporate update.
Plus Therapeutics, Inc. (Nasdaq: PSTV) acquired assets for the CNSide™ diagnostic platform to improve LM diagnosis accuracy. The company plans to develop the CNSide portfolio alongside the lead radiotherapeutic candidate and seek partnering opportunities. Topline data from the FORESEE trial met its primary endpoint, showing clinical utility in 40 patients. A full analysis is set for the SNO/ASCO Meeting in August 2024.
Plus Therapeutics, Inc. (Nasdaq: PSTV) will host an investor call on May 9th, 2024, to discuss the acquisition of CNSide assets and provide updates on the FORESEE clinical trial. The company aims to leverage the acquired assets for CNS cancers and share key insights with investors.
Plus Therapeutics, Inc. (Nasdaq: PSTV) announced a private placement financing of up to $18 million, with $6.5 million in upfront gross proceeds and the potential for an additional $11.5 million in warrant exercise proceeds. The funding involves a securities purchase agreement with new institutional investors and Company insiders. The transaction, led by AIGH Capital Management , is expected to provide the company with an estimated $34 million cash runway to support corporate goals. The financing includes the issuance of common stock and accompanying warrants, with certain investors opting for pre-funded warrants. The private placement is set to close around May 8, 2024, with proceeds intended for general corporate purposes and funding the Re-SPECT LM clinical development program.
FAQ
What is Plus Therapeutics, Inc.?
What are the main products of Plus Therapeutics?
What is Rhenium (186Re) obisbemeda?
What partnerships does Plus Therapeutics have?
What recent financial achievements has Plus Therapeutics made?
Where is Plus Therapeutics headquartered?
What clinical trials is Plus Therapeutics involved in?
Who can investors contact for more information?
What was the former name of Plus Therapeutics?
When was Plus Therapeutics founded?
